NO20063655L - Formulering for behandling av fedme og assosiert metabolisk syndrom - Google Patents

Formulering for behandling av fedme og assosiert metabolisk syndrom

Info

Publication number
NO20063655L
NO20063655L NO20063655A NO20063655A NO20063655L NO 20063655 L NO20063655 L NO 20063655L NO 20063655 A NO20063655 A NO 20063655A NO 20063655 A NO20063655 A NO 20063655A NO 20063655 L NO20063655 L NO 20063655L
Authority
NO
Norway
Prior art keywords
formulation
obesity
treatment
metabolic syndrome
extract
Prior art date
Application number
NO20063655A
Other languages
English (en)
Inventor
Marcin Krotkiewski
Original Assignee
Bringwell Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bringwell Internat Ab filed Critical Bringwell Internat Ab
Publication of NO20063655L publication Critical patent/NO20063655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår formuleringer for behandling av fedme og assosierte metabolsk syndrom. Formuleringen er en kombinasjon av spesielt utvalgte vegetabilske ekstrakter: Green tea ekstrakter inneholdende Epigallocatehin galat (EGCG), Coleus forskholii ekstrakt, Betula alba ekstrakt og Guarana eller Yerba Maté ekstrakt. I følge kliniske in vivo og in vitro studier anvendes formuleringen fra oppfinnelsen som verifisert metode for hjelp i behandling av alle kjente former for fedme og assosierte sykeligheter. En av de mest viktige fordelene ved formuleringen fra oppfinnelsen, bortsett fra akselerasjon av vekttap, er forhindring av vektøkning etter avslutning av slankekuren.
NO20063655A 2004-01-15 2006-08-14 Formulering for behandling av fedme og assosiert metabolisk syndrom NO20063655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL364411A PL209905B1 (pl) 2004-01-15 2004-01-15 Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
PCT/EP2005/000206 WO2005067952A1 (en) 2004-01-15 2005-01-12 Formulation for treating obesity and associated metabolic syndrome

Publications (1)

Publication Number Publication Date
NO20063655L true NO20063655L (no) 2006-09-22

Family

ID=34793496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063655A NO20063655L (no) 2004-01-15 2006-08-14 Formulering for behandling av fedme og assosiert metabolisk syndrom

Country Status (13)

Country Link
US (1) US20090175969A1 (no)
EP (1) EP1708726B1 (no)
JP (1) JP2007517830A (no)
KR (1) KR100826863B1 (no)
CN (1) CN1946415A (no)
AT (1) ATE411033T1 (no)
AU (1) AU2005205031A1 (no)
CA (1) CA2584191A1 (no)
DE (1) DE602005010387D1 (no)
NO (1) NO20063655L (no)
PL (1) PL209905B1 (no)
RU (1) RU2334523C2 (no)
WO (1) WO2005067952A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883472B1 (fr) * 2005-03-23 2010-09-03 Rocher Yves Biolog Vegetale Utilisation d'un acide chlorogenique en tant qu'un actif amincissant
GB0520956D0 (en) 2005-10-14 2005-11-23 Med Eq As Chewing gum
CA2628289C (en) 2005-11-04 2016-04-12 Iovate T. & P. Inc. Herbal composition for weight management
EP2001561A2 (en) * 2006-03-31 2008-12-17 DSMIP Assets B.V. Novel use of compounds and combinations of compunds for improving the physical appearance
CN101686994B (zh) 2006-10-20 2013-05-01 陶氏环球技术公司 水溶性纤维素衍生物制备用于预防或治疗代谢综合征的药物等的用途
WO2008135643A1 (fr) * 2007-05-04 2008-11-13 Nutraceutic Et Business Consulting Composition a activité lipolytique, son procédé d'obtention et utilisation de la composition.
WO2010039019A1 (es) 2008-10-03 2010-04-08 Sigma Alimentos, S.A. De C.V. Composición para promover el control de colesterol total y ldl y/o la pérdida de peso y/o la termogénesis
RU2465787C1 (ru) * 2008-10-03 2012-11-10 СИГМА АЛИМЕНТОС, С.А. де К.В. Композиция, способствующая регуляции общего холестерина и холестерина лпнп, и/или потере веса, и/или термогенезу
FR2938735B1 (fr) * 2008-11-21 2012-12-28 Holymark Composition amaigrissante, en particulier pour sportifs, administrable par voie orale et complement alimentaire integrant une telle composition.
RU2400245C1 (ru) * 2009-04-02 2010-09-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Средство для контроля уровня гликемии и профилактики сосудистых осложнений у больных с нарушениями углеводного обмена и сахарным диабетом типа 2
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN102370589B (zh) * 2010-08-11 2013-02-13 迪特克(济源)绿色生物科技有限公司 一种减肥霜及其制备方法
KR101733261B1 (ko) 2011-01-21 2017-05-08 라이온 가부시키가이샤 지방 분해 촉진 조성물
US20130177506A1 (en) * 2011-10-27 2013-07-11 Parker E. Atkins Bio-Available Chlorogenic Acid Preparations for Supplemental Human Consumption and Use
DE102014100534A1 (de) * 2014-01-17 2015-07-23 Pm-International Ag Pulverförmige Zusammensetzung zur Herstellung eines Nahrungsmittelersatzes
US20160310552A1 (en) * 2015-04-24 2016-10-27 Grethe Stoa Birketvedt Northern white kidney bean extract and ceratonia siliqua extract in combination with green tea extract in the treatment of excess weight and obesity
CN107302997A (zh) * 2016-04-19 2017-10-31 林秀霞 一种抑制脂肪蓄积的组合物及其用途
CN107638569A (zh) * 2016-07-21 2018-01-30 上海聿健生物科技有限公司 增强褐色脂肪细胞产热效率的方法和应用
US20200367547A1 (en) * 2017-03-21 2020-11-26 Pharmachem Laboratories, Llc Controlled release of phaseolamin compositions
EP3761973B1 (en) * 2018-03-05 2024-01-03 Pure Care Pro Llc Natural combination products and methods for regulation of kidney and excretory system function
KR102267472B1 (ko) * 2018-10-24 2021-06-21 전남대학교산학협력단 녹차 카테킨을 포함하는 중성지방 저감용 식품 조성물, 대사성 질환 개선용 식품 조성물 및 대사성 질환 예방 또는 치료용 약학 조성물
CN113116955B (zh) * 2021-02-24 2022-10-04 中国药科大学 一种含植物提取物的药物组合物及其应用
JP2024008717A (ja) * 2022-07-08 2024-01-19 株式会社常磐植物化学研究所 カフェイン除去マテ抽出物、抗肥満用組成物、カフェイン除去方法及びマテ抽出物の製造方法
KR20240011314A (ko) 2022-07-19 2024-01-26 대구한의대학교산학협력단 과라나 추출물을 포함하는 지방 분화 유도 억제, 지방 합성 억제 및 혈장 콜레스테롤 생성 억제용 조성물, 약학 조성물 및 건강기능식품
KR20240176420A (ko) 2023-06-15 2024-12-24 부산대학교 산학협력단 에구시 수박 (Citrullus mucosospermus)추출물을 포함하는 항비만 및 비알콜성지방간염 예방 또는 치료용 조성물
EP4552510A1 (en) 2023-11-13 2025-05-14 Mybestpharm Spolka Akcyjna Dietary supplement for comprehensive weight loss support
CN119033016A (zh) * 2024-09-29 2024-11-29 上海投创网络科技有限公司 一种减脂组合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DK339289D0 (da) * 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
FR2712191B1 (fr) * 1993-11-08 1996-03-08 Bioes Laboratoires Composition pharmaceutique ou diététique associant du ginseng et du guarana.
US5804596A (en) * 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
JPH10265328A (ja) * 1997-03-27 1998-10-06 Nippon Flour Mills Co Ltd 化粧料、ペットフード、リパーゼ阻害剤及びそれを含む食品
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
FR2788438B1 (fr) * 1999-01-14 2003-10-03 Arkopharma Laboratoires Composition pour le traitement de l'obesite et procede de traitement esthetique
JP4783882B2 (ja) * 1999-11-17 2011-09-28 三邦株式会社 新規α−アミラーゼ阻害活性物質、その製造方法及びその用途
US6610749B2 (en) * 2000-02-18 2003-08-26 Arch Development Corporation Polyhydroxylated benzene-containing compounds
DK1272154T3 (da) * 2000-04-04 2005-01-31 Color Access Inc Præparat til forbedring af hudlipidbarrierefunktionen
JP4795511B2 (ja) * 2000-07-14 2011-10-19 日本サプリメント株式会社 α−グルコシダーゼ阻害剤の製造法
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
AU2003218834A1 (en) * 2002-03-11 2003-09-22 General Nutrition Investment Company Methods for the treatment and prevention of overweight in mammals
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物

Also Published As

Publication number Publication date
JP2007517830A (ja) 2007-07-05
RU2334523C2 (ru) 2008-09-27
WO2005067952A8 (en) 2005-11-03
KR20070009562A (ko) 2007-01-18
AU2005205031A1 (en) 2005-07-28
PL364411A1 (en) 2005-07-25
US20090175969A1 (en) 2009-07-09
EP1708726B1 (en) 2008-10-15
PL209905B1 (pl) 2011-11-30
CA2584191A1 (en) 2005-07-28
ATE411033T1 (de) 2008-10-15
KR100826863B1 (ko) 2008-05-06
WO2005067952A1 (en) 2005-07-28
EP1708726A1 (en) 2006-10-11
DE602005010387D1 (de) 2008-11-27
CN1946415A (zh) 2007-04-11
RU2006129486A (ru) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20063655L (no) Formulering for behandling av fedme og assosiert metabolisk syndrom
Alzaabi et al. Flavonoids are promising safe therapy against COVID-19
Rodriguez‐Mateos et al. Cranberry (poly) phenol metabolites correlate with improvements in vascular function: A double‐blind, randomized, controlled, dose‐response, crossover study
Wiseman The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens
Ng et al. Effect of in vitro digestion on the total polyphenol and flavonoid, antioxidant activity and carbohydrate hydrolyzing enzymes inhibitory potential of selected functional plant‐based foods
Cui et al. Grape seed proanthocyanidin extracts enhance endothelial nitric oxide synthase expression through 5′-AMP activated protein kinase/Surtuin 1–Krüpple like factor 2 pathway and modulate blood pressure in ouabain induced hypertensive rats
de Jesús Romero‐Prado et al. Dietary flavonoids added to pharmacological antihypertensive therapy are effective in improving blood pressure
Branca et al. Health effects of phytoestrogens
Schini-Kerth et al. Vascular protection by natural product-derived polyphenols: in vitro and in vivo evidence
He et al. Sodium borohydride/chloranil-based assay for quantifying total flavonoids
Okello et al. Inhibition of acetylcholinesterase by green and white tea and their simulated intestinal metabolites
Yang et al. Effect of methylated tea catechins from Chinese oolong tea on the proliferation and differentiation of 3T3-L1 preadipocyte
Simonyi et al. Inhibition of microglial activation by elderberry extracts and its phenolic components
WO2005072719A8 (en) Medicinal acidic cannabinoids
Suh et al. Apigenin attenuates 2-deoxy-D-ribose-induced oxidative cell damage in HIT-T15 pancreatic β-cells
JP5638180B2 (ja) サラシア属植物の抽出物とフラボノイドを含有する食品
Basly et al. Dietary phytoestrogens: potential selective estrogen enzyme modulators?
WO2009032888A3 (en) Method for providing energy, relieving stress and mood enhancing benefits comprising administering a composition comprising cholecalciferol and a tea extract
Kawabata et al. Prenylated chalcones 4‐hydroxyderricin and xanthoangelol stimulate glucose uptake in skeletal muscle cells by inducing GLUT4 translocation
Phoboo et al. In vitro assays of anti-diabetic and anti-hypertensive potential of some traditional edible plants of Qatar
Liu et al. Cinnamon free phenolic extract regulates glucose absorption in intestinal cells by inhibiting glucose transporters
Fatmawati et al. 20 (S)-Ginsenoside Rh2 as aldose reductase inhibitor from Panax ginseng
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
Martín et al. Cocoa flavanols show beneficial effects in cultured pancreatic beta cells and liver cells to prevent the onset of type 2 diabetes
Wiseman Health effects

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application